EP0457875A4 - Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen - Google Patents

Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen

Info

Publication number
EP0457875A4
EP0457875A4 EP19910900650 EP91900650A EP0457875A4 EP 0457875 A4 EP0457875 A4 EP 0457875A4 EP 19910900650 EP19910900650 EP 19910900650 EP 91900650 A EP91900650 A EP 91900650A EP 0457875 A4 EP0457875 A4 EP 0457875A4
Authority
EP
European Patent Office
Prior art keywords
human
specificity
antibody
tumor cell
cell antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910900650
Other versions
EP0457875A1 (en
Inventor
Marc D. Better
Arnold H. Horwitz
Shau-Ping Lei
Randy R. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Xoma Corp
Original Assignee
Green Cross Corp Japan
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Xoma Corp filed Critical Green Cross Corp Japan
Publication of EP0457875A1 publication Critical patent/EP0457875A1/en
Publication of EP0457875A4 publication Critical patent/EP0457875A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19910900650 1989-11-13 1990-11-13 Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen Withdrawn EP0457875A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43501289A 1989-11-13 1989-11-13
US435012 1989-11-13

Publications (2)

Publication Number Publication Date
EP0457875A1 EP0457875A1 (en) 1991-11-27
EP0457875A4 true EP0457875A4 (en) 1993-03-03

Family

ID=23726623

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910900650 Withdrawn EP0457875A4 (en) 1989-11-13 1990-11-13 Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen

Country Status (6)

Country Link
EP (1) EP0457875A4 (en)
JP (1) JPH03206886A (en)
KR (1) KR910009284A (en)
AU (1) AU634314B2 (en)
CA (1) CA2044590A1 (en)
WO (1) WO1991007418A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
AU2610097A (en) * 1996-04-10 1997-10-29 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
IT1289608B1 (en) * 1997-02-05 1998-10-15 Angelini Ricerche Spa COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
CZ304942B6 (en) 2000-03-31 2015-02-04 Purdue Research Foundation Medicament for increasing specific elimination of tumor cell population and pharmaceutical composition containing phosphate-FITC conjugate or phosphate-dinitrophenyl
AU2002365196C1 (en) 2001-07-19 2009-08-13 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
AU2003243226A1 (en) 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
DK1592457T3 (en) 2003-01-27 2012-10-22 Endocyte Inc FOLATE-VINBLASTIN CONJUGATE AS MEDICINAL
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
CN103893778A (en) 2005-08-19 2014-07-02 恩多塞特公司 Multi-drug ligand conjugates
EP2382995A3 (en) 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
PL2187965T3 (en) 2007-08-17 2020-05-18 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JP2011500835A (en) 2007-10-25 2011-01-06 エンドサイト,インコーポレイテッド Tubulysins and preparation process
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2748613B1 (en) 2011-10-07 2021-05-05 Baxalta GmbH Oxmif as a diagnostic marker
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CA2887727A1 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
SG10201706618UA (en) 2012-11-15 2017-09-28 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
EP3495355A1 (en) 2013-10-18 2019-06-12 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3268046A4 (en) 2015-03-13 2018-11-21 Endocyte, Inc. Conjugates for treating diseases
EP4323017A1 (en) 2021-04-16 2024-02-21 Novartis AG Folate receptor-targeted radiotherapeutic agents and their use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323806A1 (en) * 1988-01-05 1989-07-12 Ciba-Geigy Ag Novel chimeric antibodies
EP0323805A2 (en) * 1988-01-05 1989-07-12 Buchegger, Franz Novel antibodies
EP0332424A2 (en) * 1988-03-09 1989-09-13 Hybritech Incorporated Chimeric antibodies directed against human carcinoembryonic antigen
EP0125023B1 (en) * 1983-04-08 1991-06-05 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023B1 (en) * 1983-04-08 1991-06-05 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
EP0323806A1 (en) * 1988-01-05 1989-07-12 Ciba-Geigy Ag Novel chimeric antibodies
EP0323805A2 (en) * 1988-01-05 1989-07-12 Buchegger, Franz Novel antibodies
EP0332424A2 (en) * 1988-03-09 1989-09-13 Hybritech Incorporated Chimeric antibodies directed against human carcinoembryonic antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9107418A1 *

Also Published As

Publication number Publication date
WO1991007418A1 (en) 1991-05-30
AU634314B2 (en) 1993-02-18
KR910009284A (en) 1991-06-28
AU6664190A (en) 1991-05-23
EP0457875A1 (en) 1991-11-27
JPH03206886A (en) 1991-09-10
CA2044590A1 (en) 1991-05-14

Similar Documents

Publication Publication Date Title
EP0457875A4 (en) Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
ZA8891B (en) Chimeric antibody with specificity to human b cell surface antigen
IL93840A0 (en) Novel monoclonal antibody to novel antigen associated with human tumors
AU4725485A (en) Monoclonal antibody to a human carcinoma tumor associated antigen
AU1085488A (en) Monoclonal antibodies to a pan-malarial antigen
IL89489A0 (en) Chimeric antibodies directed against human carcinoembryonic antigen
EP0415920A4 (en) Monoclonal antibody specific to hiv antigens
GB8820099D0 (en) Novel chimeric antibodies
HK156695A (en) Novel chimeric antibodies
ZA887771B (en) Monoclonal antibody specific to a novel epitope of the lfa-1 antigen of human t lymphocytes
HK21795A (en) Cross-protective human monoclonal antibody compositions
AU627591B2 (en) Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
EP0208902A3 (en) Monoclonal antibody specific for a pigmentation associated antigen
ZA852426B (en) Monoclonal antibody specific for human basal cell surface antigen
EP0453561A4 (en) Chimeric mouse human antibodies with specificity to hiv antigens
EP0159025A3 (en) Monoclonal antibody specific to human alpha2-plasmin
AU6609686A (en) Detection of human cancer with a monoclonal antibody specific for antigen 9p650
EP0205046A3 (en) Monoclonal antibody to human protein c
GB8808586D0 (en) Monoclonal antibody to enteroviruses
IE880021L (en) Antibodies with specificity to human b cell surface antigen
ZA856281B (en) Monoclonal antibody to a human carcinoma tumor associated antigen
IE902008L (en) HUMAN MONOCLONAL ANTIBODIES TO HIV-IMN gp120
IL106425A0 (en) Chimeric antibodies directed against human carcinoembryonic antigen
HRP940824B1 (en) Hybrid cell line for producing monoclonal antibody to a human prothymocyte antigen, antibody, and methods
ZA879133B (en) Monoclonal antibody specific to neutrophils

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930115

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19940808

R18W Application withdrawn (corrected)

Effective date: 19940808